EBS Technologies: Stimulating “Silent Neurons” To Restore Impaired Vision
EBS Technologies GMBH is shattering the current paradigm that once a person loses sight it cannot be regained. Its NEXT WAVE repetitive retinofugal alternate current stimulation technology uses noninvasive electrical stimulation to reactivate networks of “silent neurons” in patients with ophthalmic diseases or who have lost vision following brain injury.
You may also be interested in...
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
The European Medicines Agency’s human medicines committee, the CHMP, is expected to decide whether 11 drugs should be recommended for marketing approval during its latest monthly meeting, which started today.